(514) 393-1055

Chemical Computing Group Announces Agreement with IBM to Offer Joint Technology Solution for Life Sciences.

NEW ORLEANS, LOUISIANA, March 24, 2003

Today at the American Chemical Society's National Meeting, Chemical Computing Group (CCG), one of the world's leading drug discovery software companies, announced it has signed a Marketing Relationship Agreement with IBM, the world's leading information technology company. The agreement will offer innovative and scalable solutions that directly address the growing needs of Drug Discovery scientists. CCG has adapted its flagship product, the Molecular Operating Environment (MOE™), to run on powerful IBM eServer pSeries and xSeries servers running AIX and Linux operating systems, respectively, and IBM to work with IBM's DB2 database technology.

This new relationship offers drug-discovery scientists a comprehensive and integrated solution that enables them to access and share their in-house data across all platforms and operating systems in a collaborative manner. "The fact that CCG is one of the first major software vendors to have ported our entire suite of drug discovery applications to IBM's AIX operating system demonstrates our commitment to IBM. MOE's unique scalability and versatility combined with IBM's wide array of computer products means that our joint solutions give scientists greater choice than ever before. For the first time, they can operate the same powerful drug discovery software (MOE) on anything from a departmental compute cluster like the IBM eServer 1300 or 1350 Linux Cluster, on a powerful UNIX server like the IBM pSeries, or on laptop computers like the IBM ThinkPad running Windows" said Terry Higgins, CCG's Director of Research and Development.

"IBM and CCG are both committed to helping chemical researchers use information technology to speed drug discovery and gain competitive advantage," said Anne-Marie Derouault, Director, Alliances and Distribution Channel Management, IBM Life Sciences. "The integration of our leading technologies, including CCG's Molecular Operating Environment and IBM's DB2 database, creates an end-to-end solution that can help transform the discovery process today and deliver the power, performance and scalability needed for future research requirements."

CCG will showcase MOE operating on IBM platforms in booth #1211 at the American Chemical Society National Exposition in the Ernest N. Morial Convention Center in New Orleans, from March 24 to 26.

About CCG
Chemical Computing Group Inc. is a leading provider of computational applications aimed at the drug discovery and design marketplace. CCG's flagship product is the award winning Molecular Operating Environment (MOE™), which offers visualization, simulation, and methodology development in one package. MOE™ provides an integrated suite of powerful, yet intuitive chemistry software tools for HTS, Structure Based Design, Molecular modeling and Protein and Homology modeling as well as an embedded programming language for the rapid prototyping of scientific methods. Computational chemists, medicinal chemists and biologists use MOE™ in pharmaceutical companies, biotechnology companies, and universities worldwide.

CCG's headquarters are in Montreal, Canada, with offices in Lörrach, Germany and Cambridge, UK. For more information, visit www.chemcomp.com or send email to . In Asia, MOE is distributed by Ryoka Systems. Please visit www.rsi.co.jp/science.html or send E-mail to for more information.